Farletuzumab

Generic Name: Farletuzumab

Drug Type: Biotech

CAS Number: 896723-44-7

Unique Ingredient Identifier: 2O09BG0OWA

Background: Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Indication: Investigated for use/treatment in ovarian cancer.

Clinical Trials

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Neoplasms, Ovarian

Interventions: Drug: MORAb-202
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan

First Posted Date: 2022-11-14

Last Posted Date: 2025-03-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT05613088

Locations: 🇺🇸
Local Institution - 0065, Sacramento, California, United States
🇺🇸
Local Institution - 0025, San Francisco, California, United States
🇺🇸
Local Institution - 0061, Columbus, Ohio, United States

and more 47 locations

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: MORAb-202

First Posted Date: 2022-10-13

Last Posted Date: 2024-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT05577715

Locations: 🇺🇸
Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States
🇺🇸
Clermont Oncology Center, Clermont, Florida, United States
🇺🇸
Mid Florida Cancer Center - Orange City, Orange City, Florida, United States

and more 26 locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Farletuzumab ecteribulin
Drug: Prednisone
Drug: Prednisolone
Drug: Dexamethasone

First Posted Date: 2020-03-09

Last Posted Date: 2024-12-09

Lead Sponsor: Eisai Inc.

Target Recruit Count: 142

Registration Number: NCT04300556

Locations: 🇺🇸
Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States
🇺🇸
Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona, United States
🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States

and more 50 locations

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Farletuzumab Ecteribulin

First Posted Date: 2017-12-29

Last Posted Date: 2022-11-28

Lead Sponsor: Eisai Inc.

Target Recruit Count: 82

Registration Number: NCT03386942

Locations: 🇯🇵
Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 10, Koto-Ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 5, Matsuyama City, Ehime, Japan

and more 7 locations

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse

Interventions: Drug: Placebo
Drug: Farletuzumab

First Posted Date: 2014-11-13

Last Posted Date: 2021-09-02

Lead Sponsor: Eisai Inc.

Target Recruit Count: 332

Registration Number: NCT02289950

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase 2

Withdrawn

Conditions: Resectable, Non-functioning Pituitary Adenoma

First Posted Date: 2010-09-16

Last Posted Date: 2013-11-03

Lead Sponsor: Morphotek

Registration Number: NCT01203618

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

A Study of MORAb-003 in Patients With Solid Tumor

Phase 1

Completed

Conditions: Neoplasms
Solid Tumor

Interventions: Drug: MORAb-003

First Posted Date: 2010-01-14

Last Posted Date: 2020-06-11

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01049061

An Open Label Extension Study of the Efficacy of MORAb-003

Phase 2

Terminated

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: MORAb-003

First Posted Date: 2009-11-23

Last Posted Date: 2021-12-08

Lead Sponsor: Morphotek

Target Recruit Count: 3

Registration Number: NCT01018563

Locations: 🇺🇸
Sharp Memorial Hospital, Chula Vista, California, United States
🇩🇪
Nationales Centrum fur Tumorerkrandungen, Heidelberg, Germany
🇺🇸
South Texas Oncology & Hematology, San Antonio, Texas, United States

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase 3

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Farletuzumab
Drug: Carboplatin
Drug: Farletuzumab-matched placebo
Drug: Taxane

First Posted Date: 2009-02-24

Last Posted Date: 2022-12-30

Lead Sponsor: Morphotek

Target Recruit Count: 1100

Registration Number: NCT00849667

Locations: 🇺🇸
Hematology Oncology P.C., Stamford, Connecticut, United States
🇺🇸
Loyola University Chicago, Maywood, Illinois, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States

and more 339 locations

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Phase 1

Completed

Conditions: Epithelial Ovarian Cancer

First Posted Date: 2007-01-30

Last Posted Date: 2013-11-06

Lead Sponsor: Morphotek

Target Recruit Count: 24

Registration Number: NCT00428766

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy